Filter :
Standard and/or project under the direct responsibility of ISO/TC 194 Secretariat | Stage | ICS |
---|---|---|
Cleanliness of medical devices — Process design and test methods |
30.98 | |
Biological evaluation of medical devices — Part 1: Guidance on selection of tests |
95.99 | |
Biological evaluation of medical devices — Part 1: Guidance on selection of tests — Technical Corrigendum 1 |
95.99 | |
Biological evaluation of medical devices — Part 1: Evaluation and testing |
95.99 | |
Biological evaluation of medical devices — Part 1: Evaluation and testing |
95.99 | |
Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process |
95.99 | |
Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process — Technical Corrigendum 1 |
95.99 | |
Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process |
90.92 | |
Biological evaluation of medical devices — Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process |
40.00 | |
Biological evaluation of medical devices — Part 2: Animal welfare requirements |
95.99 | |
Biological evaluation of medical devices — Part 2: Animal welfare requirements |
95.99 | |
Biological evaluation of medical devices — Part 2: Animal welfare requirements |
90.92 | |
Biological evaluation of medical devices — Part 2: Animal welfare requirements |
20.00 |
|
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity |
95.99 | |
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity |
95.99 | |
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity |
90.92 | |
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity |
20.00 |
|
Biological evaluation of medical devices — Part 3: Tests for genotoxicity, carcinogenicity and reproductive and developmental toxicity |
30.98 | |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood |
95.99 | |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood |
95.99 | |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood — Amendment 1 |
95.99 | |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood |
90.93 | |
Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood — Amendment 1 |
40.20 | |
Biological evaluation of medical devices — Part 5: Tests for cytotoxicity: in vitro methods |
95.99 | |
Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity |
95.99 | |
Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity |
90.93 | |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation |
40.00 | |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation |
95.99 | |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation |
95.99 | |
Biological evaluation of medical devices — Part 6: Tests for local effects after implantation |
90.92 | |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals |
95.99 | |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals |
90.92 | |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals — Amendment 1: Applicability of allowable limits for neonates and infants |
60.60 | |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals — Technical Corrigendum 1 |
60.60 | |
Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals |
40.00 | |
Biological evaluation of medical devices — Part 8: Selection and qualification of reference materials for biological tests |
95.99 | |
Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products |
95.99 | |
Biological evaluation of medical devices — Part 9: Degradation of materials related to biological testing |
95.99 | |
Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products |
95.99 | |
Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products |
60.60 | |
Biological evaluation of medical devices — Part 10: Tests for irritation and sensitization |
95.99 | |
Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity |
95.99 | |
Biological evaluation of medical devices — Part 10: Tests for irritation and delayed-type hypersensitivity — Amendment 1 |
95.99 | |
Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization |
95.99 | |
Biological evaluation of medical devices — Part 10: Tests for skin sensitization |
60.60 | |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity |
95.99 | |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity |
95.99 | |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity |
90.92 | |
Biological evaluation of medical devices — Part 11: Tests for systemic toxicity |
30.00 |
|
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials |
95.99 | |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials |
95.99 | |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials |
95.99 | |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials |
95.99 | |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials |
60.60 | |
Biological evaluation of medical devices — Part 12: Sample preparation and reference materials — Amendment 1 |
40.00 | |
Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices |
95.99 | |
Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices |
90.20 | |
Biological evaluation of medical devices — Part 14: Identification and quantification of degradation products from ceramics |
90.20 | |
Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys |
95.99 | |
Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys |
60.60 | |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables |
95.99 | |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables |
95.99 | |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables |
90.92 | |
Biological evaluation of medical devices — Part 16: Toxicokinetic study design for degradation products and leachables |
20.00 |
|
Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances |
95.99 | |
Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents |
60.60 | |
Biological evaluation of medical devices — Part 17: Toxicological risk assessment of medical device constituents — Amendment 1 |
20.00 | |
Biological evaluation of medical devices — Part 18: Chemical characterization of materials |
95.99 | |
Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process |
60.60 | |
Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process — Amendment 1: Determination of the uncertainty factor |
60.60 | |
Biological evaluation of medical devices — Part 19: Physico-chemical, morphological and topographical characterization of materials |
95.99 | |
Biological evaluation of medical devices — Part 19: Physico-chemical, morphological and topographical characterization of materials |
90.93 | |
Biological evaluation of medical devices — Part 20: Principles and methods for immunotoxicology testing of medical devices |
90.93 | |
Biological evaluation of medical devices — Part 22: Guidance on nanomaterials |
60.60 | |
Biological evaluation of medical devices — Part 23: Tests for irritation |
60.60 | |
Biological evaluation of medical devices — Part 23: Tests for irritation — Amendment 1 |
20.00 | |
Biological evaluation of medical devices — Part 33: Guidance on tests to evaluate genotoxicity — Supplement to ISO 10993-3 |
60.60 | |
Biological evaluation of medical devices — Part 55: Interlaboratory study on cytotoxicity |
60.60 | |
Biological evaluation of medical devices — Requirements for interlaboratory studies to demonstrate the applicability of validated in vitro methods to assess the skin sensitization of medical devices |
60.60 | |
Medical products containing viable human cells — Application of risk management and requirements for processing practices |
90.93 | |
Clinical investigation of medical devices for human subjects — Part 1: General requirements |
95.99 | |
Clinical investigation of medical devices for human subjects — Part 2: Clinical investigation plans |
95.99 | |
Clinical investigation of medical devices |
95.99 | |
Clinical investigation of medical devices for human subjects — Good clinical practice |
95.99 | |
Clinical investigation of medical devices for human subjects — Good clinical practice — Technical Corrigendum 1 |
95.99 | |
Clinical investigation of medical devices for human subjects — Good clinical practice |
90.92 | |
Clinical investigation of medical devices for human subjects — Good clinical practice |
40.00 | |
Biological evaluation of medical devices — Guidance on the conduct of biological evaluation within a risk management process |
95.99 | |
Biological evaluation of medical devices — Guidance on the conduct of biological evaluation within a risk management process |
95.99 | |
Clinical evaluation of medical devices |
20.00 |
|
Biological evaluation of medical devices — Guidance on a risk-management process |
95.99 | |
Pyrogenicity — Principles and methods for pyrogen testing of medical devices |
60.60 | |
Biological evaluation of medical devices — Application of the threshold of toxicological concern (TTC) for assessing biocompatibility of medical device constituents |
90.93 | |
Medical devices utilizing human tissues and their derivatives — Application of risk management |
20.00 |
|
Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management |
95.99 | |
Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management |
95.99 | |
Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management |
60.60 | |
Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling |
95.99 | |
Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling |
95.99 | |
Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling |
60.60 | |
Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents |
90.93 | |
Medical devices utilizing animal tissues and their derivatives — Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes |
90.93 | |
Sources of hazard information for medical device constituents |
10.99 |
|
Biological evaluation of absorbable medical devices — Part 1: General requirements |
90.20 | |
Cardiovascular biological evaluation of medical devices — Guidance for absorbable implants |
60.60 |
No matching records found. Please try changing the filter settings.